New Brain Cancer Therapy Shrinks Tumors in Just 5 Days

Scientists have achieved rapid tumor shrinkage in patients with one of the most aggressive brain cancers, using a therapy that reprograms the body's own immune cells to fight back.

The experimental treatment targets glioblastoma, a devastating brain cancer that typically resists standard therapies and almost always returns. Published in The New England Journal of Medicine, the early trial results showed tumors beginning to shrink within just five days of a single treatment.

The study involved patients with recurrent glioblastoma who had already tried surgery, radiation, and chemotherapy without lasting success. After receiving the new CAR-T therapy, some patients experienced near-complete tumor regression, with one patient's tumor dropping significantly within two days.

CAR-T therapy works by removing a patient's immune cells, training them in a lab to recognize cancer better, then returning them to the body. What makes this version special is its dual approach: it attacks multiple markers on tumor cells simultaneously, making it harder for the cancer to escape.

The therapy is also delivered directly into the brain rather than through the bloodstream. This precise delivery allows the modified cells to act right where they're needed most.

Glioblastoma has long been one of medicine's toughest challenges. It grows rapidly, invades surrounding tissue, and resists most treatments. Even with the best care available, average survival is typically less than two years.

Why This Inspires

For decades, glioblastoma patients have faced limited options and modest improvements at best. The speed of these results marks something genuinely different in the fight against this disease.

While researchers emphasize this is early-stage work with a small group of patients, the rapid response suggests immunotherapy may finally be breaking through against solid brain tumors. The effects weren't permanent in all cases, and tumors eventually regrew in some patients, but scientists are already working on extending the therapy's durability.

The findings could ripple beyond glioblastoma too. Success with one of the hardest-to-treat cancers may open doors for immunotherapy against other stubborn solid tumors that have resisted previous approaches.

Experts describe the tumor shrinkage as both rapid and dramatic, words rarely associated with glioblastoma treatment. For patients who've exhausted other options, this represents something that's been scarce in brain cancer care: a genuinely promising new direction forward.